PATENT CLAIM ANALYSIS

Application Number: 15775986
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "453000"]

Abstract:
Disclosed are bruceolides for the treatment of cancer, and other diseases, selectively targeting unwanted cells. The disclosed bruceolides may include a site specific cleavable moiety inhibiting the chemotoxic activity until cleaved, i.e., removed, within and/or near a cancer to be treated. As to facilitate selective delivery to cancer tumors, the disclosed bruceolides may be loaded into, attached to or otherwise carried by nanoparticles.

Claim (Index 23):
The chemotherapeutic formulation according to  claim 22 , wherein the at least one targeting moiety is a ligand for at least one of human epidermal growth factor, prostate specific membrane antigen, nucleolin, sialyl lewis X, cytotoxic T cell antigen-4, tenascin-C, platelet derived growth factor receptor, and pigpen.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 93.0
- Lexical Diversity: 1.40385
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15652947', '12573591', '14434300', '13891341', '12744982']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7306144279634904
- 35 USC 102 Novelty (BERT): 0.4981874368912211
- Combined Prediction Score: 0.7073717288562634
- Mean Citation Score: 234.968964
- Max Citation Score: 241.52362
- Similarity Product: 179.11333520374652

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test